Posted on 01/24/2012 5:40:57 PM PST by neverdem
Reviewed by Zalman S. Agus, MD; Emeritus Professor
University of Pennsylvania School of Medicine.
|
|
|
|
|
Action Points
A highly sensitive troponin test revealed evidence of subclinical heart damage in patients with hyperglycemia but no known coronary artery disease or heart failure, with particularly high enzyme levels in those with diabetes, according to a community-based population study. Baseline levels of glycated hemoglobin (HbA1c) were linearly associated with results of a high-sensitivity cardiac troponin-T (hs-cTnT) test, reported Elizabeth Selvin, PhD, MPH, from the Johns Hopkins Bloomberg School of Public Health, and colleagues. Compared with normal levels of HbA1c (<5.7%), those in the pre-diabetic range (5.7% to 6.4%) had hs-cTnT values about 25% higher, while those with HbA1c levels equal to or greater than 6.5% had hs-cTnT values about 70% higher, according to the study published in the Jan. 31 issue of the Journal of the American College of Cardiology. The use of these high-sensitivity troponin assays has shown promise in predicting cardiovascular events and death in patients with congestive heart failure and coronary heart disease, Selvin and colleagues noted. Since hyperglycemia is associated with coronary heart disease, diabetes, and death, various researchers have hypothesized that subclinical heart damage associated with hyperglycemia might be an early biomarker that could influence treatment. In the current study, the authors enrolled 9,661 participants from the Atherosclerosis Risk in Communities (ARIC) study. The researchers defined elevated levels of hs-cTnT as those above the previously reported 99th percentile value (14 ng/L) in healthy people. In this cohort, 7.3% had elevated enzymes. The mean age of the population was 56 and nearly 60% were women. Those with higher HbA1c levels were more likely to be African American and hypertensive and have higher body mass index and higher LDL cholesterol, as well as lower HDL cholesterol. When researchers fully adjusted for covariates, they found that every 1% increase in HbA1c was associated with a 0.7 ng/L bump in hs-cTnT (P<0.001). When adjusted for age, sex, and race, those with pre-diabetic levels of HbA1c were 51% more likely to have elevated hs-cTnT values (OR 1.51, 95% CI 1.23 to 1.85). Similarly, those with diabetic HbA1c levels were four times more likely to have elevated troponin (OR 4.09, 95% CI 3.25 to 5.15). Adjusting for cardiovascular risk factors and then for fasting glucose did not significantly change the risk. A fasting glucose level higher than 100 mg/dL was associated with elevated hs-cTnT, but only in the analysis that adjusted for age, sex, and race. That HbA1c is a better marker of subclinical myocardial damage is consistent with other studies, researchers wrote. "Our data support new recommendations for the use of HbA1c for the diagnosis of diabetes and identification of persons at high risk for development of complications," they concluded. In an accompanying editorial, James A. de Lemos, MD, and Scott M. Grundy, MD, PhD, from the University of Texas Southwestern Medical Center in Dallas, did not deny that low levels of circulating troponin may indicate subclinical injury. However, they suggested that elevated troponin levels might be secondary to diabetes-related kidney disease, particularly because the HbA1c and troponin measurements in this study were not taken at the same time. In addition, medications such as sulfonylurea agents may have contributed to cardiac injury in the interim, they said. "Before troponin levels can be considered a validated intermediate phenotype in the pathway to heart failure, additional studies are needed linking changes in troponins with cardiovascular and noncardiovascular outcomes, and investigating the role of specific therapies on troponin release and subsequent events," they wrote. "These studies should be a high priority as they have the potential to facilitate earlier interventions to prevent heart failure." Selvin and colleagues noted the study is limited because the HbA1c and hs-cTnT values were not obtained at the same visit so it cannot be ruled out that some participants might have had elevated troponin levels at the baseline visit. There is also a selection bias concern because those who died prior to the last visit were excluded. Although they did adjust for confounders, there may still be some residual in this observational study. The research was supported by grants from the National Institutes of Health. Ballantyne reported receiving a grant from Roche Diagnostics through the Baylor University Medical Center. All other authors reported no conflicts. De Lemos reported receiving grant support from Alere, Roche Diagnostics, and Abbott Diagnostics and is a consultant for Johnson & Johnson and Tethys Diagnostics. Grundy reported no relevant relationships.
From the American Heart Association:
|
|
|
|
Primary source: Journal of the American College of Cardiology Source reference: Rubin J, et al "Chronic hyperglycemia and subclinical myocardial injury" J Am Coll Cardiol 2012; 59; 484-489. Source reference: de Lemos JA, et al "Low levels of circulating troponin as an intermediate phenotype in the pathway to heart failure" J Am Coll Cardiol 2012; 59: 490-492. |
|
|
|
|
This little tidbit was in the middle of the article. How many millions of people with diabetes may have been damaged by this med?
I don't know, but there's been a warning message on sulfonylureas for a while, maybe since the nineties, if not longer.
I don’t even know where to start. Just blah blah blah...this study strikes me as a waste of time.
I'm not sure what you know about cardiac enzymes, so here's the troponin test.
I do them.
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.